Akari Therapeutics (AKTX) Non-Current Debt (2024 - 2025)

Akari Therapeutics (AKTX) posted quarterly Non-Current Debt of $100000.0 for Q3 2025, down 85.71% on a QoQ basis from $700000.0 in Q2 2025.

Akari Therapeutics (AKTX) Non-Current Debt (2024 - 2025) Analysis & Trends

Akari Therapeutics (AKTX) has reported Non-Current Debt for 2 consecutive years, with $100000.0 the latest figure, recorded in Q3 2025.

Quarterly Non-Current Debt changed N/A year-over-year to $100000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $100000.0 (changed N/A YoY) and the FY2024 annual result came in at $1.7 million, changed N/A from the prior year.
Non-Current Debt fell to $100000.0 in Q3 2025 per AKTX's latest filing, from $700000.0 in the prior quarter.
Over the last five years, Non-Current Debt for AKTX reached as high as $1.7 million in Q4 2024 and fell as low as $100000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Akari Therapeutics	86.55 Mn	86.55 Mn	-	-

Download Data